Literature DB >> 8221233

Two factors, IRF1 and KBF1/NF-kappa B, cooperate during induction of MHC class I gene expression by interferon alpha beta or Newcastle disease virus.

R M Ten1, V Blank, O Le Bail, P Kourilsky, A Israël.   

Abstract

The expression of class I genes of the Major Histocompatibility Complex is stimulated by IFN. The promoter of these genes contains an interferon response sequence (IRS) which overlaps the major enhancer. These elements are recognized by several protein factors, including IRF-1, which binds the IRS, and KBF1/NF-kappa B, which binds the enhancer. We demonstrate here that infection by Newcastle Disease Virus (NDV) results in an increased expression of class I genes, by a mechanism partially different from that of IFN, but that in both cases the cooperative action of IRF1 and KBF1/NF-kappa B is required. In F9 embryonal carcinoma cells, where KBF1/NF-kappa B activity cannot be detected, both types of stimuli are ineffective.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221233

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  13 in total

1.  Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.

Authors:  Pegah Johansson; Ann Jansson; Ulla Rüetschi; Lars Rymo
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

2.  Drosophila immunity. A sequence homologous to mammalian interferon consensus response element enhances the activity of the diptericin promoter.

Authors:  P Georgel; C Kappler; E Langley; I Gross; E Nicolas; J M Reichhart; J A Hoffmann
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

3.  A mutant cell line defective in response to double-stranded RNA and in regulating basal expression of interferon-stimulated genes.

Authors:  D W Leaman; A Salvekar; R Patel; G C Sen; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

4.  In adenovirus type 12 tumorigenic cells, major histocompatibility complex class I transcription shutoff is overcome by induction of NF-kappaB and relief of COUP-TFII repression.

Authors:  Shihe Hou; Hancheng Guan; Robert P Ricciardi
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 5.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

6.  Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides.

Authors:  K Suzuki; A Mori; K J Ishii; J Saito; D S Singer; D M Klinman; P R Krause; L D Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB.

Authors:  A Kumar; Y L Yang; V Flati; S Der; S Kadereit; A Deb; J Haque; L Reis; C Weissmann; B R Williams
Journal:  EMBO J       Date:  1997-01-15       Impact factor: 11.598

8.  Nuclear factor-kappaB motif and interferon-alpha-stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells.

Authors:  Elisabeth Naschberger; Thomas Werner; Ana B Vicente; Eric Guenzi; Kristin Töpolt; René Leubert; Clara Lubeseder-Martellato; Peter J Nelson; Michael Stürzl
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

9.  ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs.

Authors:  Piotr J Balwierz; Mikhail Pachkov; Phil Arnold; Andreas J Gruber; Mihaela Zavolan; Erik van Nimwegen
Journal:  Genome Res       Date:  2014-02-10       Impact factor: 9.043

10.  Interferon enhances tumor necrosis factor-induced vascular cell adhesion molecule 1 (CD106) expression in human endothelial cells by an interferon-related factor 1-dependent pathway.

Authors:  S Lechleitner; J Gille; D R Johnson; P Petzelbauer
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.